Skip to main content
Atrás
Watch Compare

Iterum Therapeutics plc

Calidad de datos: 83%
ITRM
Nasdaq Manufacturing Chemicals
$0.03
▲ $0.03 (—)
Cap. Mercado: 1.60 M
Precio
$0.03
Cap. Mercado
1.60 M
Rango del Día
$0.03 — $0.05
Rango de 52 Semanas
$0.01 — $1.42
Volumen
49,297,937
Apertura $0.04
Promedio 50D / 200D
$0.21
85.44% below
Promedio 50D / 200D
$0.52
94.20% below

Quick Summary

Puntos Clave

Negative free cash flow of -19.53 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROIC-59.78%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio2.13
Interest Coverage-4.12

Valoración

PE (TTM)
-0.06
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -0.1 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -26.96 M
ROE N/A ROA -81.06%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -19.53 M
ROIC -59.78% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.13
Interest Coverage -4.12 Asset Turnover N/A
Working Capital 7.30 M Tangible Book Value -26.09 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.06 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1221.46%
Market Cap 1.60 M Enterprise Value 10.64 M
Per Share
EPS (Diluted TTM) -0.72 Revenue / Share N/A
FCF / Share -0.37 OCF / Share -0.37
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 72.43%
SBC-Adj. FCF -19.77 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — 0.0 0.0
Net Income -24.77 M -38.37 M -44.43 M -91.56 M -52.01 M
EPS (Diluted) -1.26 -2.96 -3.63 — —
Gross Profit — — — — —
Operating Income -18.70 M -47.47 M -30.38 M -24.54 M -32.13 M
EBITDA — — — — —
R&D Expenses 10.46 M 39.99 M 17.62 M 10.71 M 21.07 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 3.31 M — — — —
Income Tax 240,000.0 613,000.0 301,000.0 705,000.0 743,000.0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 44.60 M 26.26 M 66.83 M 91.51 M 32.79 M
Total Liabilities 48.68 M 32.66 M 38.83 M 41.28 M 83.35 M
Shareholders' Equity -4.08 M -6.40 M 28.00 M 50.23 M -50.56 M
Total Debt 31.22 M 11.22 M 12.71 M 6.93 M 22.46 M
Cash & Equivalents 24.13 M 6.07 M 21.09 M 27.45 M 14.51 M
Current Assets 24.79 M 25.60 M 62.44 M 83.27 M 21.47 M
Current Liabilities 17.61 M 13.52 M 9.06 M 12.94 M 41.70 M